Literature DB >> 21151389

Selective central nervous system tropism of primary central nervous system lymphoma.

Liuyan Jiang1, Laura A Marlow, Simon J Cooper, Christina V Roemeling, David M Menke, John A Copland, Han W Tun.   

Abstract

Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS). We performed an experiment in which lymphoma cells from a PCNSL patient were implanted subcutaneously in an athymic mouse. The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL). We did not find any evidence of lymphoma at the site of implantation or other locations. The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature.

Entities:  

Keywords:  Lymphoma; central nervous system; tropism

Mesh:

Substances:

Year:  2010        PMID: 21151389      PMCID: PMC2993226     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  Intravascular large B-cell lymphoma presenting with mass lesions in the central nervous system: a report of five cases.

Authors:  Hiroshi Imai; Kazuyoshi Kajimoto; Masashi Taniwaki; Ikuo Miura; Yoshihiro Hatta; Yoshio Hashizume; Masatoshi Watanabe; Taizo Shiraishi; Shigeo Nakamura
Journal:  Pathol Int       Date:  2004-04       Impact factor: 2.534

2.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.

Authors:  Sophie Camilleri-Broët; Emmanuelle Crinière; Philippe Broët; Vincent Delwail; Karima Mokhtari; Anne Moreau; Michèle Kujas; Martine Raphaël; Wafae Iraqi; Catherine Sautès-Fridman; Philippe Colombat; Khê Hoang-Xuan; Antoine Martin
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  An update on primary central nervous system lymphoma.

Authors:  Fabio M Iwamoto; Lisa M DeAngelis
Journal:  Hematol Oncol Clin North Am       Date:  2006-12       Impact factor: 3.722

4.  Differential gene expression in central nervous system lymphoma.

Authors:  James L Rubenstein; Arthur Shen; Tracy T Batchelor; Cigall Kadoch; Patrick Treseler; Marc A Shuman
Journal:  Blood       Date:  2009-01-01       Impact factor: 22.113

5.  The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells.

Authors:  L M Larocca; D Capello; A Rinelli; S Nori; A Antinori; A Gloghini; A Cingolani; A Migliazza; G Saglio; S Cammilleri-Broet; M Raphael; A Carbone; G Gaidano
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

Review 6.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

7.  B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas.

Authors:  I C Anthony; D H Crawford; J E Bell
Journal:  Brain       Date:  2003-05       Impact factor: 13.501

8.  BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.

Authors:  Kristina M Braaten; Rebecca A Betensky; Laurence de Leval; Yoshifumi Okada; Fred H Hochberg; David N Louis; Nancy L Harris; Tracy T Batchelor
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

9.  Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma.

Authors:  Justine R Smith; Rita M Braziel; Samantha Paoletti; Martin Lipp; Mariagrazia Uguccioni; James T Rosenbaum
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Pathway analysis of primary central nervous system lymphoma.

Authors:  Han W Tun; David Personett; Karen A Baskerville; David M Menke; Kurt A Jaeckle; Pamela Kreinest; Brandy Edenfield; Abba C Zubair; Brian P O'Neill; Weil R Lai; Peter J Park; Michael McKinney
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

  10 in total
  11 in total

1.  Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.

Authors:  Liuyan Jiang; Zhimin Li; Laura E Finn; David A Personnet; Brandy Edenfield; James M Foran; Kurt A Jaeckle; Ronald Reimer; David M Menke; Rhett P Ketterling; Han W Tun
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

2.  Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Authors:  Felicitas Strehlow; Sandra Bauer; Peter Martus; Michael Weller; Patrick Roth; Uwe Schlegel; Sabine Seidel; Carmen Scheibenbogen; Agnieszka Korfel; Stephan Kreher
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

Review 3.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

4.  Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.

Authors:  Samantha S Soldan; Chenhe Su; R Jason Lamontagne; Nicholas Grams; Fang Lu; Yue Zhang; James D Gesualdi; Drew M Frase; Lois E Tolvinski; Kayla Martin; Troy E Messick; Jonathan T Fingerut; Ekaterina Koltsova; Andrew Kossenkov; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2021-06-09       Impact factor: 6.823

5.  Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Authors:  Sabrina Donnou; Claire Galand; Valérie Touitou; Catherine Sautès-Fridman; Zsuzsanna Fabry; Sylvain Fisson
Journal:  Adv Hematol       Date:  2012-02-12

6.  Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Authors:  Qiu Yushi; Zhimin Li; Christina A Von Roemeling; Heike Doeppler; Laura A Marlow; Betty Y S Kim; Derek C Radisky; Peter Storz; John A Copland; Han W Tun
Journal:  Oncotarget       Date:  2016-05-31

7.  Biomarkers Reflecting The Destruction Of The Blood-Brain Barrier Are Valuable In Predicting The Risk Of Lymphomas With Central Nervous System Involvement.

Authors:  Wenjun Yu; Mengya Si; Li Li; Ping He; Zhiqiang Fan; Qiaoxin Zhang; Xiaoyang Jiao
Journal:  Onco Targets Ther       Date:  2019-11-11       Impact factor: 4.147

8.  Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Authors:  Zhimin Li; Yushi Qiu; David Personett; Peng Huang; Brandy Edenfield; Jason Katz; Darius Babusis; Yang Tang; Michael A Shirely; Mehran F Moghaddam; John A Copland; Han W Tun
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 9.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

10.  Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.

Authors:  Siria A Lemma; Milla Kuusisto; Kirsi-Maria Haapasaari; Raija Sormunen; Tuula Lehtinen; Tuula Klaavuniemi; Mine Eray; Esa Jantunen; Ylermi Soini; Kaija Vasala; Jan Böhm; Niina Salokorpi; Petri Koivunen; Peeter Karihtala; Jussi Vuoristo; Taina Turpeenniemi-Hujanen; Outi Kuittinen
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.